Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma.

PubWeight™: 1.36‹?› | Rank: Top 10%

🔗 View Article (PMID 12112110)

Published in Ann Neurol on May 01, 2002

Authors

Steven Vernino1, Paul Tuite, Charles H Adler, James F Meschia, Bradley F Boeve, Peter Boasberg, Joseph E Parisi, Vanda A Lennon

Author Affiliations

1: Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. verns@mayo.edu

Articles citing this

Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58

Paraneoplastic syndromes of the CNS. Lancet Neurol (2008) 4.62

Rapidly progressive dementia. Ann Neurol (2008) 3.00

Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol (2010) 2.77

Antibodies and neuronal autoimmune disorders of the CNS. J Neurol (2009) 2.40

Rapidly progressive dementia. Neurol Clin (2007) 1.58

Paraneoplastic neurological syndromes. Curr Opin Neurol (2012) 1.29

Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol (2011) 1.28

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry (2008) 1.22

Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20

The adaptive immune system in diseases of the central nervous system. J Clin Invest (2012) 1.17

Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol (2013) 1.15

Autoimmune chorea in adults. Neurology (2013) 1.11

Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood (2014) 1.06

Current approaches to the treatment of paraneoplastic encephalitis. Ther Adv Neurol Disord (2011) 0.99

Chorea and related disorders. Postgrad Med J (2004) 0.99

Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. J Neurol (2011) 0.96

Brain-reactive antibodies and disease. Annu Rev Immunol (2013) 0.94

Update on paraneoplastic neurologic disorders. Oncologist (2010) 0.77

Update on the Non-Huntington's Disease Choreas with Comments on the Current Nomenclature. Tremor Other Hyperkinet Mov (N Y) (2012) 0.76

Encephalomyeloneuropathy with CRMP-5 antibodies in a patient with a primary mediastinal serinoma. Neurol Neuroimmunol Neuroinflamm (2015) 0.76

Paraneoplastic Choreoathetosis in a Patient with Small Cell Lung Carcinoma and Anti-CRMP5/CV2: A Case Report. Case Rep Neurol (2016) 0.75

Articles by these authors

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25

The spectrum of neuromyelitis optica. Lancet Neurol (2007) 11.83

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20

Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85

Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20

The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology (2008) 5.94

2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke (2015) 5.64

Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52

Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12

Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87

Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med (2014) 4.70

Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol (2007) 4.68

Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain (2007) 4.50

Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (2012) 4.36

Brain abnormalities in neuromyelitis optica. Arch Neurol (2006) 4.28

Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07

Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02

Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95

Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93

Defining mild cognitive impairment in Parkinson's disease. Mov Disord (2007) 3.92

Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology (2013) 3.70

Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66

3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain (2007) 3.53

PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40

Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc (2007) 3.32

Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27

Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol (2006) 3.26

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol (2007) 3.25

Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet (2011) 3.16

Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol (2012) 3.11

Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One (2012) 3.11

Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08

Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04

Case series of painful legs and moving toes: clinical and electrophysiologic observations. Mov Disord (2008) 3.04

A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol (2007) 2.99

Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91

Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease. Arch Neurol (2008) 2.80

Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80

Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76

Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal. Neurology (2013) 2.73

Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73

Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol (2009) 2.67

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65

Increased risk of type 2 diabetes in Alzheimer disease. Diabetes (2004) 2.61

Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain (2007) 2.58

Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol (2008) 2.58

Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol (2009) 2.55

Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50

Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49

Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet (2008) 2.48

Assessing the temporal relationship between cognition and gait: slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci (2012) 2.48

Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol (2008) 2.46

Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol (2013) 2.46

Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain (2012) 2.43

Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry (2008) 2.39

Risk factors for dementia with Lewy bodies: a case-control study. Neurology (2013) 2.38

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet (2011) 2.35

The Carotid Revascularization Endarterectomy versus Stenting Trial: credentialing of interventionalists and final results of lead-in phase. J Stroke Cerebrovasc Dis (2010) 2.35

Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology (2013) 2.34

High prevalence of stroke symptoms among persons without a diagnosis of stroke or transient ischemic attack in a general population: the REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Arch Intern Med (2006) 2.32

Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol (2010) 2.31

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30

Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol (2013) 2.29

Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol (2003) 2.29

MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27

Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med (2008) 2.26

Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol (2010) 2.26

Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19

Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. Stroke (2008) 2.19

Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord (2014) 2.17

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol (2002) 2.17

Influence of sex on outcomes of stenting versus endarterectomy: a subgroup analysis of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Lancet Neurol (2011) 2.15

Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol (2006) 2.13

Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A (2011) 2.11

Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11

Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol (2013) 2.10